Goodwin Advises LimmaTech Biologics on $780 Million Acquisition by Lilly
The Life Sciences team advised LimmaTech Biologics AG on entry into a definitive agreement to be acquired by Lilly. Under the terms of the agreement, Lilly will acquire LimmaTech for up to $780 million in cash, inclusive of an upfront payment and additional potential payments based upon the achievement of certain clinical and regulatory milestones.
LimmaTech Biologics is at the forefront of combating the global antimicrobial resistance epidemic based on its track record in vaccine technology and clinical candidate development. The company is leveraging its proprietary self-adjuvanting and multi-antigen vaccine platform alongside additional disease-specific vaccine approaches to prevent increasingly untreatable microbial infections. With decades of expertise and an expanding, robust pipeline, the LimmaTech team is dedicated to generating protective solutions to deliver transformative value worldwide. LimmaTech Biologics is backed by specialist healthcare investors, including Adjuvant Capital, BNP Paribas Asset Management Alts, Novo Holdings REPAIR Impact Fund, and Tenmile.
The Goodwin team was led by Rob Puopolo, Felipe Heiderich, Sam Beavers, Amine Assouad, Connor McMillan, Nick Allison, Alexandra Haas, Daniel Karelitz, Matt Dunay, Arman Oruc, Kevin Walsh, Danielle Fong, Heath Ingram, Elizabeth Mulkey, and Malhar Naik.
For more information on the deal, please read the press release.